Abstract:Background: Non–small cell lung cancer (NSCLC) is the most common histologic type of lung cancer, accounting for 70–85% of all lung cancers. It has brought a heavy burden of disease and financial cost to families, society, and the nation of China. Patients have differing preferences for treatment because of their varying physical conditions and socioeconomic backgrounds, which ultimately affects the choice of treatment as well as treatment outcomes. For better and sustained health outcomes, it is vital to understand patients' preferences. We can then provide medical services to match these preferences and needs rather than basing treatment on our clinical viewpoints alone.Objectives: The aim of this study was to elicit patient preferences for treatment using a discrete-choice experiment and to explore the value/importance that patients place on the different attributes of treatment in order to provide a basis for clinical decision making and patient health management.Methods: The study was conducted with NSCLC patients from three typical hospitals in southwestern China. After identifying patient-relevant treatment attributes via literature review and qualitative semi structured interviews, a discrete-choice experiment (DCE) including seven patient-relevant attributes was conducted using a fractional factorial SAS design. The empiric data analyses of patients were performed using mixed logit models.Results: NSCLC patients (N = 202) completed a survey via a face-to-face interview. Among the seven attributes, the following were considered important: progression-free survival, disease control rate, cost, weakness/fatigue, and nausea/vomiting; mode of administration and rash were considered less important. A clear preference for an increase in progression-free survival and disease control rate was demonstrated. Compared with 5 months of progression-free survival, respondents were willing to pay more (19,860 RMB) for 11 months of progression-free survival (coef.: 0.687). Compared with a 60% rate of disease control, respondents were willing to pay more (19,940 RMB) for a 90% rate of disease control (coef.: 0.690).Conclusions: This study demonstrates the value of DCEs in determining patient preferences for the treatment of NSCLC. The results indicate that not only efficacy factors (such as progression-free survival and disease control rate) were considered but also other factors (such as side effects and treatment costs) and trade-offs between attributes were held to be important. These results are in accord with expectations and can provide evidence for more effective and efficient treatment results. Furthermore, the current results can increase benefits if the presented therapies can be designed, assessed, and chosen based on patient-oriented findings.

Application of Discrete selection Experiment in Treatment Preferences of Tumor Population

Preferences of cancer survivors for follow-up care: a systematic review of discrete choice experiments

Doctor's Choice Preference for Non-small Cell Lung Cancer Treatment

Eliciting Older Cancer Patients' Preferences for Follow-Up Care to Inform a Primary Healthcare Follow-Up Model in China: A Discrete Choice Experiment.

Whether preferences of gastric cancer patients after surgery for follow-up change over time? Analysis based on discrete choice experiment

A Study of Patient Preferences for the Treatment of Non–small Cell Lung Cancer in Western China: A Discrete-Choice Experiment

Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UK

Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers

Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkers

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Patient Preferences and Shared Decision Making for the Traditional Chinese Medicine Treatment of Lung Cancer: A Discrete Choice Experiment Study.

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

Optimal Sequential Enrichment Designs for Phase II Clinical Trials.

On Estimation of Optimal Dynamic Treatment Regimes with Multiple Treatments for Survival Data-With Application to Colorectal Cancer Study

Criteria of tumor regression grade and its application in diagnosis and treatment of rectal cancer

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Information needs preferences of Chinese colorectal cancer patients receiving chemotherapy: A discrete choice experiment

Study on Disease Treatment Preference and Willingness Payment in Patients with Non-small Cell Lung Cancer

Attributes Used for Cancer Screening Discrete Choice Experiments: A Systematic Review

Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment

Exploring treatment options in cancer: Tumor treatment strategies